Corporate Fact Sheet
OVERVIEW
Emergent BioSolutions is a global specialty biopharmaceutical
company dedicated to one simple mission — to protect and
enhance life. We develop, manufacture, and deliver a portfolio
of medical countermeasures against biological and chemical
threats as well as emerging infectious diseases. We also develop
and commercialize therapeutics and other specialty products
for hospitals and clinics in the areas of hematology /oncology,
transplantation, infectious diseases and autoimmune disorders.
Through our work, we envision protecting and enhancing 50
million lives with our products by 2025.
OPERATIONS
° Headquarters: Gaithersburg, MD
° Manufacturing Facilities: United States, Canada
° Product Development Sites: United States, Canada, Germany
° Services: Contract manufacturing
° Product Portfolio: Vaccines, antibody therapeutics,
and antimicrobials focused on infectious diseases,
hematology/oncology, transplantation, autoimmune
diseases, and healthcare protective products
PORTFOLIO AS OF DECEMBER 2015
BIODEFENSE PORTFOLIO
PRODUCT
DISEASE / THERAPEUTIC AREA
STAGE
TYPE
BioThrax® (Anthrax Vaccine Adsorbed)
Anthrax
Marketed
Vaccine
RSDL® (Reactive Skin Decontamination Lotion Kit)
Chemical Decontamination
Marketed
Medical Device
VIGIV [Vaccinia Immune Globulin Intravenous (Human)]
Smallpox
Marketed
Therapeutic
BAT ® [Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)]
Botulism
Marketed
Therapeutic
Anthrasil™ [Anthrax Immune Globulin Intravenous (Human)]
Anthrax
Marketed
Therapeutic
PRODUCT CANDIDATE
DISEASE / THERAPEUTIC AREA
STAGE
TYPE
NuThrax™ (anthrax vaccine adsorbed with CPG 7909 adjuvant)
Anthrax
Phase 21
Vaccine
VAX161C 2
Pandemic Influenza
Phase 1
Vaccine
PRODUCT
DISEASE / THERAPEUTIC AREA
STAGE
TYPE
WinRho SDF [Rho (D) Immune Globulin Intravenous (Human)]
Immune Thrombocytopenic Purpura and
Hemolytic Disease of the Newborn
Marketed
Therapeutic
HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)]
Hepatitis B
Marketed
Therapeutic
IXINITY ® [coagulation factor IX (recombinant)]
Hemophilia B
Marketed
Therapeutic
VARIZIG® [Varicella Zoster Immune Globulin (Human)]
Chickenpox
Marketed
Therapeutic
Additional preclinical programs focused on infectious diseases
BIOSCIENCES PORTFOLIO
®
PRODUCT CANDIDATE
DISEASE / THERAPEUTIC AREA
STAGE
TYPE
Otlertuzumab (humanized anti-CD37 therapeutic*)
Chronic Lymphocytic Leukemia
Phase 2
Therapeutic
MOR209/ES414 (humanized anti-PSMA and CD3 therapeutic**)
Metastatic Castration-resistant Prostate Cancer
Phase 1
Therapeutic
Additional preclinical therapeutic programs focused on oncology, Alzheimer's disease
*ADAPTIR ™ – mono-specific protein therapeutics
**ADAPTIR ™ – bi-specific protein therapeutics
1 Status reflects both clinical and nonclinical development under the FDA Animal Rule
2 Pandemic Influenza vaccine licensed from VaxInnate
PLATFORM TECHNOLOGIES
PRODUCT PIPELINE
PLATFORM TECHNOLOGY
DESCRIPTION
ADAPTIR™
Scaffold for multi-specific
molecules for the development
of therapeutics
— Metastatic Castration-resistant
Prostate Cancer
—m
ono-specific protein therapeutics
Scaffold for mono-specific
molecules for the development
of therapeutics
— Chronic Lymphocytic Leukemia
MVAtor™
Recombinant, live, attenuated
viral vector for the development
of vaccines
— Ebola
(modified vaccinia virus Ankara vector)
PLATFORM TECHNOLOGY
DESCRIPTION
MARKETED PRODUCTS
Hyperimmunes
— Human
Purified gamma globulin (IgG) containing polyclonal antibodies to
specific antigen(s) obtained from fractionation of human plasma
— W inRho® SDF, HepaGam B®,
VARIZIG®, VIGIV, Anthrasil™
— Equine
Purified immune globulin fragments derived from polyclonal antibodies
to specific antigen(s) obtained from fractionation of equine plasma
— BAT®
EMERGARD™ (auto-injector)
Ruggedized, military-grade auto-injector device
(modular protein technologies)
— multi-specific protein therapeutics
CLINICAL
PRECLINICAL
— A nti-CD86xmono-IL10
Autoimmune and Inflammatory
—R
espiratory Syncytial Virus (RSV)
— Universal flu
RECENT BUSINESS HIGHLIGHTS
° FDA Approves sBLA to Expand the Label of BioThrax to Include Post-Exposure Prophylaxis
° Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program
®
° Announces Plan to Implement Tax-Free Spin-Off of Biosciences Business Into a Separate Publicly-Traded Company
° Expands Biodefense Business Through Launch of a Military-Grade Auto-Injector Device for Chemical Threats
° Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies
° Oxford University, GSK, and Emergent BioSolutions Announce Initiation of a Prime Boost Study of Ebola Vaccine Candidates
° Expands Commercial Product Portfolio with FDA Approval of IXINITY , a Recombinant Factor IX Treatment for Hemophilia B
™
° Receives FDA Approval of Anthrasil , Emergent’s Anthrax Immune Globulin, for Use in the Treatment of Inhalational Anthrax
®
FINANCIAL HIGHLIGHTS
Total Revenue
Net Income
(dollars in millions)
Assets
(dollars in millions)
52
450
EBITDA
(dollars in millions)
(dollars in millions)
945
92
84
286
10
273
282
11
12
37
313
31
13
14
10
23
24
11
12
13
500
14
10
547
564
11
12
63
627
13
14
10
48
49
11
12
13
14
Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.
CONTACT INFORMATION
CORPORATE
400 Professional Drive, Suite 400
Gaithersburg, MD 20879 USA
Tel: 240-631-3200
Fax:240-631-3203
Business Development: Darren Buchwald, BD@ebsi.com
Investor Relations: Robert Burrows, burrowsr@ebsi.com
Corporate Communications: Tracey Schmitt Lintott, schmittt@ebsi.com
www.emergentbiosolutions.com
www.biothrax.com
www.rsdl.com
Emergent BioSolutions, Protected by Emergent BioSolutions™, ADAPTIR ™, Anthrasil™, BAT®, BioThrax ®, HepaGam B®, IXINITY ®, MVAtor™, NuThrax™, PreviThrax™, RSDL®, VARIZIG ®, and WinRho® and any and all
Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries.
All rights reserved.
11003-12 /15